Evoke Pharma Inc has 5 Schedule 13D or 13G filings on record since 2025-09-08. 1 holder's latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Klein Roger M. | 10.5% | 163,000 | SCHEDULE 13D, 2025-11-12 | 2025-11-04 |
| Morgan Stanley | 0% | 31 | SCHEDULE 13G/A, 2025-12-05 | 2025-11-30 |
| Nantahala Capital Management, LLC | 0% | 0 | SCHEDULE 13D/A, 2025-12-19 | 2025-12-17 |
Purpose of Transaction (Item 4)
Nantahala Capital Management, LLC
Item 4 is amended by the addition of the following: As disclosed by the Issuer in a Current Report on Form 8-K (the "Closing 8-K") filed with the U.S. Securities and Exchange Commission on December 17, 2025, on the same date Parent completed the acquisition of the Company, by causing Merger Sub to merge with and into the Company (the "Merger") pursuant to the Merger Agreement without a vote of the Company stockholders in accordance with Section 251(h) of the General Corporation Law of the State of Delaware (the "DGCL"). At the Effective Time, Merger Sub was merged with and into the Company, the separate existence of Merger Sub ceased and the Company continued as a wholly owned subsidiary of Parent (the "Surviving Corporation"). At the Effective Time, each Share issued and outstanding immediately prior to the Effective Time (other than Shares (i) owned by the Company, Parent, Merger Sub or any direct or indirect wholly owned subsidiary of Parent or Merger Sub prior to the Effective Time, (ii) irrevocably accepted for payment pursuant to the Offer, or (iii) held by any stockholder who is entitled to demand and has properly and validly demanded their statutory right of appraisal of such Shares in accordance with, and in compliance in all respects with, Section 262 of the DGCL), including each Shares then beneficially owned by the Reporting Persons, was automatically cancelled and extinguished and converted into the right to receive an amount in cash equal to the $11.00 per …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-12-19; the filing has the rest
Klein Roger M.
On November 4, 2025, Mr. Klein acquired, or in his capacity as trustee caused the Krieger Charitable Trust (the "Charitable Trust") to acquire, all 163,000 shares of Common Stock of the Issuer currently owned by the Reporting Persons (the "Klein Shares"). This acquisition came after the Issuer announced in a Current Report on Form 8-K (the "Merger 8-K") filed with the U.S. Securities and Exchange Commission on November 4, 2025, that on November 3, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger") with QOL Medical, LLC, a Delaware limited liability company ("Parent"), and certain of its affiliates (together with Parent, "QOL"), pursuant to which QOL will commence a tender offer (the "Offer") to acquire all of the outstanding shares of Common Stock for $11.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (the "Offer Price"). Mr. Klein is not affiliated with QOL, did not have any access to insider or non-public information, and acquired, or caused to be acquired, the Klein Shares pursuant to his personal investment strategy and the Charitable Trust's investment strategy. The Reporting Persons do not seek to take an active role in the Merger, have no present activist intent with respect to the Merger and did not intend to acquire a notable block of the Issuer's outstanding Common Stock. Mr. Klein intends to sell (or cause to be sold) a small number of the Klein Shares, on November 6, 2025 to reduce his …The first part of Item 4 of the SCHEDULE 13D filed 2025-11-12; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-08 | Morgan Stanley | 10.5% | SCHEDULE 13G |
| 2025-11-04 | Nantahala Capital Management, LLC | 15.99% | SCHEDULE 13D/A |
| 2025-11-12 | Klein Roger M. | 10.5% | SCHEDULE 13D |
| 2025-12-05 | Morgan Stanley | 0% | SCHEDULE 13G/A |
| 2025-12-19 | Nantahala Capital Management, LLC | 0% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Evoke Pharma Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.